secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001493152-22-030277
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q3 2022 revenue $14.5M (+5% YoY); net loss widens to $2.4M
------------------------------------------------------------------------

- Revenue of $14.5M, up 5% from $13.8M in Q3 2021, driven by 12% biologics growth from OsteoFactor and OsteoVive Plus launches.
- Gross margin improved to 54.6% from 52.2% on better capacity utilization.
- Net loss of $2.4M ($0.03 loss per share) vs. $1.8M ($0.02) in prior-year period.
- Non-GAAP adjusted EBITDA loss of $0.9M, compared to $0.6M loss a year ago.
- CEO cited recent $9.75M private placement to support growth and expects full operating capacity by Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/0001493152-22-030277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer